Acura Pharmaceuticals, Inc. (ACUR) - Financial and Strategic SWOT Analysis Review

Date: May 3, 2016
Pages: 39
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A4D176632B6EN
Leaflet:

Download PDF Leaflet

Acura Pharmaceuticals, Inc. (ACUR) - Financial and Strategic SWOT Analysis Review
Acura Pharmaceuticals, Inc. (ACUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Acura Pharmaceuticals, Inc. (Acura) is a specialty pharmaceutical company. It researches, develops, and commercializes products to address medication abuse and misuse. The company’s proprietary platform technologies Aversion and Limitx technologies are used to address methods of product tampering associated with opioid abuse, Its Impede Technology is indicated for minimizing the extraction and conversion of pseudoephedrine into methamphetamine. Oxaydo (formerly Oxecta), the company’s product candidate, is an immediate release opioid analgesic, for the treatment of moderate to severe pain. The company markets its products through wholesale pharmaceutical distributors and directly to chain drug stores. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals, Inc. Key Recent Developments

May 02, 2016: Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Feb 29, 2016: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results
Nov 04, 2015: Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results
Aug 03, 2015: Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results
Jun 29, 2015: Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx Abuse Deterrent Technology

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Acura Pharmaceuticals, Inc. - Key Facts
Acura Pharmaceuticals, Inc. - Key Employees
Acura Pharmaceuticals, Inc. - Key Employee Biographies
Acura Pharmaceuticals, Inc. - Major Products and Services
Acura Pharmaceuticals, Inc. - History
Acura Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Acura Pharmaceuticals, Inc. - Business Description
Acura Pharmaceuticals, Inc. - Corporate Strategy
Acura Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Acura Pharmaceuticals, Inc. - Strengths
Strength - Research and Development Activities
Strength - Proprietary Technologies
Strength - Lead Product: Nexafed
Acura Pharmaceuticals, Inc. - Weaknesses
Weakness - Operating Loss Carryforward
Weakness - Patent Infringement Concerns
Acura Pharmaceuticals, Inc. - Opportunities
Opportunity - Growing Market for Opioid Analgesics
Opportunity - Emerging Markets
Opportunity - Changing Demographics
Acura Pharmaceuticals, Inc. - Threats
Threat - Competitive Environment
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Acura Pharmaceuticals, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Acura Pharmaceuticals, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 29, 2016: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results
Nov 04, 2015: Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results
Aug 03, 2015: Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results
Jun 29, 2015: Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx Abuse Deterrent Technology
May 04, 2015: Acura Pharmaceuticals Announces First Quarter 2015 Financial Results
Mar 02, 2015: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Acura Pharmaceuticals, Inc., Key Facts
Acura Pharmaceuticals, Inc., Key Employees
Acura Pharmaceuticals, Inc., Key Employee Biographies
Acura Pharmaceuticals, Inc., Major Products and Services
Acura Pharmaceuticals, Inc., History
Acura Pharmaceuticals, Inc., Subsidiaries
Acura Pharmaceuticals, Inc., Key Competitors
Acura Pharmaceuticals, Inc., Ratios based on current share price
Acura Pharmaceuticals, Inc., Annual Ratios
Acura Pharmaceuticals, Inc., Interim Ratios
Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Acura Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Acura Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
Acura Pharmaceuticals, Inc., Ratio Charts
Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Acura Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Acura Pharmaceuticals, Inc. (ACUR) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: